Table 1

Relationship between the expression of PRAF3 and clinical features

clinical features

esophageal squamous cell carcinoma


PRAF3-positive n (%)

PRAF3-negative n (%)

test

P


Total

24

33


Age (year)


< 60

13/24 (54.2)

19/33 (57.6)

0.0656

0.7979


≥ 60

11/24 (45.8)

14/33 (42.4)


Gender


Male

17/24 (70.8)

25/33 (75.8)

0.1738

0.6768


Female

7/24 (29.2)

8/33 (24.2)


Pathological grading


Well

11/24 (45.9)

6/33 (18.2)

5.9991

0.0498


Moderately

8/24 (33.3)

12/33 (36.4)


Poorly

5/24 (20.8)

15/33 (45.4)


Tumor location


Upper 1/3 middle 1/3

15/24 (62.5)

23/33 (70.0)

0.3239

0.5693


Lower 1/3

9/24(37.5)

10/33 (30.0)


Tumor stage


T1/T2

13/24 (54.2)

8/33 (24.2)

5.347

0.0208


T3/T4

11/24 (45.8)

25/33 (75.8)


Lymph node metastasis


Negative

14/24 (58.3)

10/33 (30.3)

4.4785

0.0343


Positive

10/24 (41.7)

23/33 (69.7)


Shi et al. BMC Cancer 2012 12:97   doi:10.1186/1471-2407-12-97

Open Data